Immune to Cancer: The CRI Blog
-
ASCO20 Update: Cellular Immunotherapies, Genomics, and COVID-19
Several promising cellular immunotherapies were discussed at ASCO20, including those for solid cancers; plus updates on the cancer…
-
AACR20 Day 2 Highlights: COVID-19, Adoptive Cell Therapy, and Checkpoint Immunotherapy Insights
The second day of AACR’s annual meeting heard from experts at cancer centers in COVID-19 hotspots around…
-
How Immunotherapy for Esophageal Cancer is Making an Impact
Dr. Deirdre Cohen discusses recent advances in immunotherapy for esophageal cancer, including biomarkers, checkpoint inhibitors, cell-based therapies,…
-
Meet Dr. Yvonne Chen, One of Our New Lloyd J. Old STAR Scientists
We spoke with Dr. Yvonne Chen to learn more about her work in chemical engineering to fight…
-
The Promise of CAR T Cell Therapy in 2019 and Beyond
Dr. Michel Sadelain discusses what’s next in CAR T cell therapy, including the remarkable benefits and the…
-
ASCO19 Recap: Caring for Every Patient, Learning from Every Patient
ASCO19 highlighted a number of immunotherapy developments, including those relating to long-term survival, introducing immunotherapy earlier, biomarkers,…
-
ASCO19 Day 5 Update: CAR T Cells for Pleural Cancers and More Melanoma News
The final day of ASCO19 covered CAR T cells for pleural cancers and long-term updates on several…
-
ASCO19 Day 2 Update: Biomarkers in Checkpoint Immunotherapy, Targeting Macrophages, and Cellular Immunotherapies
The second day at ASCO19 highlighted biomarkers that may have value in the context of PD-1 checkpoint…
-
Dr. Robert Schreiber and Interferon Gamma
By redefining our understanding of the relationship between cancer and the immune system, Dr. Robert Schreiber has…